Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life
Future Virology, 08/08/2013
Ingiliz P – HIV–positive patients are in urgent need for new treatment options, as they often have more aggressive liver disease and lower reponse rates with the current standard treatments. These initial results are very promising, and HIV/HCV–coinfected patients seem to now have equal response rates as monoinfected patients, as long as drug–drug interactions remain under control.
The licensing of the first HCV protease inhibitors will lead to a dramatic increase in cure rates for patients with chronic genotype 1 hepatitis C.
The addition of a third drug, such as telaprevir, to the standard treatment with pegylated interferon and ribavirin has become the new standard of care in the western world.
While a shortening of the treatment duration is often possible, side effects are likely to increase with these products.
The experience with telaprevir in HIV/HCV–coinfected patients is limited to one Phase II trial.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.